Radioactive injection shows promise in slowing neuroendocrine tumor growth

NCT ID NCT05459844

Ongoing Disease control Sponsor: Sinotau Pharmaceutical Group Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 3 study tested a radioactive drug called Lutetium-177 oxodotreotide against a high dose of the standard drug octreotide in 196 people with advanced neuroendocrine tumors that had stopped responding to treatment. The main goal was to see if the radioactive drug could delay tumor growth better than octreotide. Participants received either four injections of the radioactive drug or regular octreotide shots, and their tumors were monitored over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lutetium-177 oxodotreotide injection (a type of radioactive drug)
What this could lead to: If this treatment works, it could offer a more effective option to slow tumor growth in people with advanced neuroendocrine tumors that are no longer controlled by standard therapy.
What could go wrong: This is a Phase 3 trial, but results are not yet published. The radioactive drug may cause side effects like kidney or bone marrow damage, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine tumor, grade 1/2 neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMORS

Contacts and locations

Locations

Affiliated Hospital of Southwest Medical University

Luzhou, Sichuan, 646000, China
Chinese PLA General Hospital

Beijing, Beijing Municipality, 100853, China
Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China
Henan Provincial People's Hospital

Zhengzhou, Henan, 450003, China
Mianyang Central Hospital

Mianyang, Sichuan, 621099, China
Nanjing First Hospital

Nanjing, Jiangsu, 210006, China
Qilu Hospital of Shandong University

Jinan, Shandong, 250012, China
The First Affiliated Hospital of AFMU

Xi'an, Shaanxi, 710032, China
The First Affiliated Hospital of Jinan University

Guangzhou, Guangdong, 510630, China
The First Affiliated Hospital of Shanxi Medical University

Taiyuan, Shanxi, 030012, China
The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, 510080, China
The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, 710061, China
The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, 361003, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450052, China
The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310003, China
The First Afilliated Hospital of Fujian Medical University

Fuzhou, Fujian, 350005, China
The first hospital of Jilin University

Changchun, Jilin, 130021, China
Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, 300060, China
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

Wuhan, Hubei, 430030, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China
West China Hospital of Sichuan University

Chengdu, Sichuan, 610041, China
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, 310022, China
Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.